1. Home
  2. IMMX
  3. Earnings

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K

Nov 12, 2026

0001493152-26-051402

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

– Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement –

– Interim NEXICART-2 clinical trial results selected for oral presentation at ASH 2026 –

LOS ANGELES, November 12, 2026 (GLOBE NEWSWIRE) – Immix Biopharma, Inc. (“Immix”, the “Company”, “we” or “us”), a global leader in AL amyloidosis, today reported an update on corporate progress and financial results for the quarter ended September 30, 2026.

Recent NXC-201 Progress

-Positive clinical data: 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity indicating potential to reach up to 98% complete response rate in the future.

-Immix continues to advance its AL Amyloidosis launch readiness activities across commercial site activation, provider and payer engagement, manufacturing activities, and healthcare professional education.

Immix plans for its BLA submission in mid-2027, and NEXICART-3 front line trial initiation in the first half of 2027.

Interim NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at 68th American Society of Hematology (ASH) Annual Meeting

On Monday, December 14, 2026, NXC-201 NEXICART-2 interim clinical data will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Commercial Launch Preparation Continues with Strengthened Team

Immix has appointed David He, MD, PhD as Senior Vice President, Head of Technical Operations. Dr. He has contributed in a senior role to two approved BCMA CAR-Ts, CARVYKTI® and FUCASO®. Dr. He will lead chemistry, manufacturing, and controls at Immix, further accelerating the Company’s planned path to commercialization. Prior to Immix, Dr. He served as the Chief Technology Officer from pre-BLA to commercial-stage at IASO Biotherapeutics and as the Vice President, Technical Operations at Legend Biotech, as well as in a senior chemistry, manufacturing, and controls positions at Boehringer Ingelheim, and other senior roles.

Immix has appointed Karin McIntosh as Senior Vice President, Head of Regulatory Affairs. Karin has contributed to multiple FDA drug programs, including JANUVIA® (FDA+EMA), EMFLAZA® (FDA), ELZONRIS® (FDA+EMA), and most recently, the approval of TREGZI® (FDA, 2026). Karin will lead regulatory affairs at Immix in the United States and globally. Prior to Immix, Karin was Vice President, Head of Regulatory Affairs at Orca Bio and held senior regulatory positions at Stemline Therapeutics, PTC Therapeutics, Merck, and Pfizer.

1

Additionally, Immix has appointed additional key team members across its Commercial, Regulatory, Quality, Medical Affairs teams, and as Medical Science Liaisons.

Upcoming Events

-In addition to NEXICART-2 interim clinical data being presented at ASH on Monday December 14, 2026, the Company will also present at the 45th Annual J.P. Morgan Healthcare Conference being held in San Francisco from January 11 - 14, 2027.

Financial Results for the Third Quarter Ended September 30, 2026

-Immix reported $340.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which is expected to provide operating runway into mid-2028.

-Immix reported $15.9 million in operating expenses for the third quarter ended September 30, 2026.

About AL Amyloidosis

Amyloid light-chain (AL) amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death.

AL amyloidosis is the most common form of amyloidosis according to the National Institutes of Health. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

About

NXC-201

NXC-201

is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.

2

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (Nasdaq: IMMX) is a global leader in AL amyloidosis. AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic l

About Immix Biopharma Inc. (IMMX) Earnings

This page provides Immix Biopharma Inc. (IMMX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on IMMX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: